| Oct 25 |
J&J reports positive data for Tremfya in low body surface area psoriasis
|
| Oct 25 |
New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
|
| Oct 25 |
Is Kenvue Stock a Buy Now?
|
| Oct 25 |
J&J’s comeback kid Spravato heads for blockbuster status
|
| Oct 24 |
Johnson & Johnson (JNJ): Legal Challenges Over Talc Products Impact Dow Performance
|
| Oct 24 |
Johnson & Johnson Investing $2B to Build Pharma Factory in North Carolina
|
| Oct 24 |
If You Invested $10,000 In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?
|
| Oct 24 |
Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress
|
| Oct 24 |
Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government
|
| Oct 24 |
J&J’s Asish Xavier on biotech’s rebound in a volatile era
|
